Mesoblast Limited
MESO · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -10.26 | 0.00 | 0.65 |
| FCF Yield | -1.08% | -0.81% | -0.46% | -1.13% |
| EV / EBITDA | -68.94 | -79.23 | -248.33 | -107.94 |
| Quality | ||||
| ROIC | -4.66% | -4.66% | -3.45% | -3.45% |
| Gross Margin | -231.13% | -231.13% | -107.85% | -107.85% |
| Cash Conversion Ratio | 0.54 | – | 0.43 | – |
| Growth | ||||
| Revenue 3-Year CAGR | 31.86% | 14.66% | -9.53% | -10.46% |
| Free Cash Flow Growth | -16.62% | -23.39% | 1.76% | -12,186.05% |
| Safety | ||||
| Net Debt / EBITDA | 1.68 | 1.70 | -9.32 | -9.32 |
| Interest Coverage | 0.00 | 0.00 | -3.86 | -3.86 |
| Efficiency | ||||
| Inventory Turnover | 1.05 | 1.05 | 0.14 | 0.14 |
| Cash Conversion Cycle | 202.81 | 192.98 | 434.73 | 434.73 |